Mortality in patients with non-functioning pituitary adenoma

被引:0
作者
Metaxia Tampourlou
Athanasios Fountas
Georgia Ntali
Niki Karavitaki
机构
[1] University of Birmingham,Institute of Metabolism and Systems Research, College of Medical and Dental Sciences
[2] Centre for Endocrinology,Department of Endocrinology
[3] Diabetes and Metabolism,Department of Endocrinology, Diabetes and Metabolism
[4] Birmingham Health Partners,undefined
[5] Queen Elizabeth Hospital,undefined
[6] University Hospitals Birmingham NHS Foundation Trust,undefined
[7] Evangelismos Hospital,undefined
来源
Pituitary | 2018年 / 21卷
关键词
Non-functioning pituitary adenomas; Mortality; Hypopituitarism;
D O I
暂无
中图分类号
学科分类号
摘要
Non-functioning pituitary adenomas (NFA) are benign pituitary neoplasms not associated with clinical evidence of hormonal hypersecretion. A substantial number of patients with NFA have morbidities related to the tumor and possible recurrence(s), as well as to the treatments offered. Studies assessing the long-term mortality of patients with NFA are limited. Based on the published literature of the last two decades, overall, the standardized mortality ratios in this group suggest mortality higher than that of the general population with deaths attributed mainly to circulatory, respiratory and infectious causes. Women seem to have higher mortality ratios, and assessment of time trends suggests improvement over the years. There is no consensus on predictive factors of mortality but those most consistently identified are older age at diagnosis and high doses of glucocorticoid substitution therapy. Well designed and of adequate power studies are needed to establish the significance of factors compromising the survival of patients with NFA and to facilitate improvements in long-term prognosis.
引用
收藏
页码:203 / 207
页数:4
相关论文
共 158 条
[1]  
Asa SL(2017)From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal Endocr Relat Cancer 24 C5-C8
[2]  
Casar-Borota O(2006)High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium J Clin Endocrinol Metab 91 4769-4775
[3]  
Chanson P(2010)Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK) Clin Endocrinol 72 377-382
[4]  
Delgrange E(2010)Incidence of pituitary adenomas in Northern Finland in 1992–2007 J Clin Endocrinol Metab 95 4268-4275
[5]  
Earls P(2000)Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality J Clin Endocrinol Metab 85 1420-1425
[6]  
Ezzat S(2009)Nonfunctioning pituitary adenomas: the Oxford experience Nat Rev Endocrinol 5 519-522
[7]  
Grossman A(2009)Radiation-induced hypopituitarism Endocr Relat Cancer 16 733-772
[8]  
Ikeda H(2016)Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up Eur J Endocrinol 174 137-145
[9]  
Inoshita N(2015)Efficacy and complications of pituitary irradiation Endocrinol Metab Clin N Am 44 117-126
[10]  
Karavitaki N(2014)Diagnosis and management of prolactinomas and non-functioning pituitary adenomas BMJ 349 g5390-73